# Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006

> **NCT00119639** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 32 (actual)

## Conditions studied

- Kidney Diseases

## Interventions

- **DRUG:** Sorafenib (BAY43-9006, Nexavar)

## Key facts

- **NCT ID:** NCT00119639
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** —
- **Final completion:** 2005-12
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2009-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00119639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00119639, "Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of BAY 43-9006". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT00119639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*